Novo Nordisk Advances DKK 15 Billion Share Buyback, Holds 0.6% in Treasury Stock as of 10 April 2026
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Novo Nordisk ( (NVO) ) has provided an announcement.
Novo Nordisk on 13 April 2026 reported progress under the B share repurchase programme it launched on 4 February 2026 as part of a broader plan to buy back up to DKK 15 billion of shares over 12 months. Between 7 and 10 April 2026, the company repurchased 1,040,000 B shares, bringing total purchases since 4 February to 11,007,992 B shares for DKK 2.84 billion at an average price of DKK 257.56.
Following these transactions, Novo Nordisk held 28,397,791 B shares as treasury stock, equivalent to 0.6% of its 4,465,000,000 total A and B shares, highlighting a continued commitment to shareholder returns through buybacks. The ongoing programme, conducted under EU Safe Harbour rules, signals confidence in the company’s financial position and earnings outlook while incrementally reducing the free float, a dynamic closely watched by investors in one of the healthcare sector’s largest European issuers.
The most recent analyst rating on (NVO) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Neutral.
The score reflects strong underlying financial quality and attractive valuation, partially offset by a very weak technical setup (downtrend across all key moving averages) and a cautious near-term outlook from management, including guidance for declining 2026 sales and operating profit amid pricing and policy headwinds.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, with a core focus on treating serious chronic diseases rooted in its heritage in diabetes care. The company employs about 68,800 people in 80 countries, markets its therapies in roughly 170 countries, and lists its B shares on Nasdaq Copenhagen and ADRs on the New York Stock Exchange, underscoring its broad international investor base.
Its portfolio and strategy centre on pioneering scientific breakthroughs, expanding access to medicines and working to prevent and ultimately cure chronic conditions, positioning Novo Nordisk as a major player in the global market for diabetes and other serious chronic disease treatments. This scale and focus make capital allocation decisions, including share repurchase programmes, particularly relevant for both equity investors and healthcare stakeholders following the group’s long‑term growth and returns profile.
Average Trading Volume: 23,353,498
Technical Sentiment Signal: Sell
Current Market Cap: $167.3B
See more insights into NVO stock on TipRanks’ Stock Analysis page.
